Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ribozymes apt for assays

Genomics-based discovery has churned out numerous new targets, but there has been a lag in accompanying functional assays. Furthermore, most assays are tailored to a specific target and therefore lack applicability in industrialized, high throughput research.

A publication in this month's Nature

Read the full 421 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers